Illumina partners with SomaLogic for proteomics assay

By The Science Advisory Board staff writers

January 10, 2022 -- Illumina has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan proteomics assay to Illumina's current and future high-throughput next-generation sequencing (NGS) platforms.

By combining Somascan's high-plexity technology with Illumina's existing and future high-throughput NGS platforms, researchers can analyze thousands of samples for more than 10,000 protein targets, the company said.

Illumina will begin a multiyear development effort to integrate SomaLogic's protein target volume with Illumina's sequencing technologies, informatics toolsets, and Dragen software to create a full end-to-end NGS workflow solution.

llumina will further support expansion in proteomics by harnessing the scalability of its NGS platforms and its broad installed base across academic research institutions, medical centers, and biopharma companies while SomaLogic focuses on expansion and innovation of its market-leading protein panel.

No financial details of the partnership were disclosed.

Gretel, Illumina partner to develop synthetic data for genomic research
Gretel announced a collaboration with Illumina to create synthetic genomic data that can be accessed by medical researchers globally. The companies also...
Illumina supports Norway's pioneering precision medicine study
Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling in...
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...
SomaLogic, CM Life Sciences release protein panels for biotech research
SomaLogic and CM Life Sciences II have released customizable protein panels for pharmaceutical, biotechnology, and academic research purposes.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter